Avenue Therapeutics, Inc, a specialty pharmaceutical company, acquires, licenses, develops, and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, which is in Phase III clinical trials to treat moderate to moderately severe post-operative pain. The company was founded in 2015 and is based in New York, New York.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone781-652-4500
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees6
Next Earnings Date11/13/2019 (Estimated)
OptionableNot Optionable
Avenue Therapeutics (NASDAQ:ATXI) Frequently Asked Questions
What is Avenue Therapeutics' stock symbol?
Avenue Therapeutics trades on the NASDAQ under the ticker symbol "ATXI."
How were Avenue Therapeutics' earnings last quarter?
Avenue Therapeutics Inc (NASDAQ:ATXI) posted its earnings results on Wednesday, August, 14th. The company reported ($0.43) EPS for the quarter, beating the Zacks' consensus estimate of ($0.48) by $0.05. View Avenue Therapeutics' Earnings History.
When is Avenue Therapeutics' next earnings date?
What price target have analysts set for ATXI?
2 analysts have issued 1 year target prices for Avenue Therapeutics' stock. Their predictions range from $10.00 to $11.00. On average, they anticipate Avenue Therapeutics' share price to reach $10.50 in the next year. This suggests a possible upside of 80.1% from the stock's current price. View Analyst Price Targets for Avenue Therapeutics.
What is the consensus analysts' recommendation for Avenue Therapeutics?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avenue Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Avenue Therapeutics.
Has Avenue Therapeutics been receiving favorable news coverage?
Media coverage about ATXI stock has been trending very negative this week, according to InfoTrie Sentiment. The research group rates the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Avenue Therapeutics earned a news sentiment score of -3.9 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 3.0 out of 10, indicating that recent news coverage is unlikely to have an effect on the company's share price in the immediate future. View News Stories for Avenue Therapeutics.
Are investors shorting Avenue Therapeutics?
Avenue Therapeutics saw a decrease in short interest during the month of September. As of September 30th, there was short interest totalling 12,600 shares, a decrease of 7.4% from the August 30th total of 13,600 shares. Based on an average daily volume of 14,700 shares, the short-interest ratio is presently 0.9 days. Approximately 0.2% of the shares of the company are sold short. View Avenue Therapeutics' Current Options Chain.
Who are some of Avenue Therapeutics' key competitors?
Some companies that are related to Avenue Therapeutics include Lexicon Pharmaceuticals (LXRX), MediciNova (MNOV), Obseva (OBSV), Constellation Pharmaceuticals (CNST), Neptune Wellness Solutions (NEPT), CymaBay Therapeutics (CBAY), AC Immune (ACIU), Corbus Pharmaceuticals (CRBP), Kindred Biosciences (KIN), Prothena (PRTA), OptiNose (OPTN), CytomX Therapeutics (CTMX), Protagonist Therapeutics (PTGX), Theratechnologies (THERF) and Avid Bioservices (CDMO).
What other stocks do shareholders of Avenue Therapeutics own?
Who are Avenue Therapeutics' key executives?
Avenue Therapeutics' management team includes the folowing people:
- Dr. Lindsay Allan Rosenwald, Exec. Chairman (Age 64)
- Dr. Lucy Lu, Pres, CEO & Director (Age 44)
- Mr. Joseph Walter Vazzano, CFO, Principal Financial Officer & Company Sec. (Age 35)
- Dr. Scott A. Reines, Interim Chief Medical Officer (Age 72)
When did Avenue Therapeutics IPO?
(ATXI) raised $30 million in an initial public offering on Tuesday, June 27th 2017. The company issued 5,000,000 shares at $5.00-$7.00 per share. Oppenheimer served as the underwriter for the IPO and National Securities Corp. was co-manager.
How do I buy shares of Avenue Therapeutics?
Shares of ATXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Avenue Therapeutics' stock price today?
One share of ATXI stock can currently be purchased for approximately $5.83.
How big of a company is Avenue Therapeutics?
Avenue Therapeutics has a market capitalization of $96.54 million. The company earns $-21,550,000.00 in net income (profit) each year or ($2.10) on an earnings per share basis. Avenue Therapeutics employs 6 workers across the globe.View Additional Information About Avenue Therapeutics.
What is Avenue Therapeutics' official website?
How can I contact Avenue Therapeutics?
Avenue Therapeutics' mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The company can be reached via phone at 781-652-4500 or via email at [email protected]
MarketBeat Community Rating for Avenue Therapeutics (NASDAQ ATXI)
MarketBeat's community ratings are surveys of what our community members think about Avenue Therapeutics and other stocks. Vote "Outperform" if you believe ATXI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATXI will underperform the S&P 500 over the long term. You may vote once every thirty days.
